الصفحة الرئيسية>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Vebufloxacin (Flumenique)

Vebufloxacin (Flumenique)

رقم الكتالوجGC33708

يُظهر Vebufloxacin (Flumenique) (Flumenique ؛ OPC7241 ؛ DM8966) نشاطًا قويًا مضادًا للبكتيريا ضد البكتيريا موجبة الجرام والسلبية.

Products are for research use only. Not for human use. We do not sell to patients.

Vebufloxacin (Flumenique) التركيب الكيميائي

Cas No.: 79644-90-9

الحجم السعر المخزون الكميّة
1mg
534٫00
متوفر
5mg
1057٫00
متوفر
10mg
1801٫00
متوفر
20mg
3171٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Vebufloxacin (Flumenique; OPC7241; DM8966) exhibits potent antibacterial activity against gram-positive and -negative bacteria.

A series of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids is synthesized and tested for antibacterial activities. Among them, Vebufloxacin (OPC-7241) exhibits potent antibacterial activity against gram-positive and -negative bacteria, including Staphylococcus aureus and Pseudomonas aeruginosa, and OPC-7251 shows potent activity characteristically against Propionibacterium acnes[1].

[1]. Ishikawa H, et al. Studies on antibacterial agents. I. Synthesis of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids. Chem Pharm Bull (Tokyo). 1989 Aug;37(8):2103-8.

مراجعات

Review for Vebufloxacin (Flumenique)

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Vebufloxacin (Flumenique)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.